Chunlan Dong, Xiaoxi Xu, Qinyun Ma*, Teng Lu, Zhe Sun, Wubin Qian, Sheng Guo, Qian Shi, and Frank Xing
*Fudan University Affiliated Huashan Hospital, Shanghai 200040, China
To advance preclinical immuno-oncology drug discovery, CrownBio has developed a syngeneic model screening platform for evaluating the in vivo efficacy of immuno-oncology agents (MuScreen™, Poster A64).
To allow the combination of clinically promising therapeutic strategies which activate immune cells with targeting the unique genetic characteristics of a tumor model, we thoroughly characterized the mutation profiles of these syngeneic cell lines and examined drug response profiles through in vitro screening.
This work provides an in vitro system for evaluating combination effectiveness when targeting both immune checkpoint markers and oncogenic targets in preclinical studies.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-02-19
2021-10-28
landing_page
PDX/Databases